Thu Sep 19 06:11:30 UTC 2024: ## Nanobiotix Stock Dips Despite Positive Analyst Rating
**New York, NY – September 19, 2024** – Nanobiotix S.A. (NASDAQ: NBTX), a clinical-stage biotechnology company, saw its share price decline by 1.4% on Wednesday, closing at $4.93. Trading volume was significantly lower than average, with only 6,684 shares changing hands.
Despite the dip, the company received a positive outlook from Guggenheim analysts on August 28th. They issued a “buy” rating and a $12.00 price objective on the stock, signaling confidence in Nanobiotix’s potential.
Nanobiotix is known for developing innovative treatments for cancer and other medical needs. Its lead product candidate, NBTXR3, is a nanoparticle-based therapy for various cancers including soft tissue sarcoma, head and neck cancers, and liver cancers.
While Wednesday’s price drop may have disappointed some investors, the company’s positive outlook and ongoing development of NBTXR3 suggest that Nanobiotix remains a player to watch in the biotechnology sector.
First Piper 